Insiders who reported open-market trades in the last 12 months at the companies David A. Rosa files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
David J. Wambeke - $737K in NMTC purchases and sales in the last 12 months
Mark Christianson - $55K in NMTC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
David A. Rosa is a corporate insider, tracked as CEO & President, Director of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has David A. Rosa submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
David A. Rosa is CEO & President, Director of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). 8 SEC Form 4 filings on record going back to 2024, most recently on 28 August 2026.
Recent transactions
7
The latest 7 SEC Form 4 transactions reported by David A. Rosa.
InsiderAlpha's records for David A. Rosa go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
